Editor's note

Originally published November 2021. VacZine Analytics' commercial intelligence on the EBV vaccine market is available in VAMV056 - Epstein-Barr Virus Vaccines Forecast (2022), covering prophylactic and therapeutic target product profiles with forecasts to 2040 across Western economies.

The Hidden Burden of EBV

Epstein-Barr virus (EBV) is a herpesvirus transmitted primarily via oral secretions. Primary infection in adolescence and young adulthood typically presents as infectious mononucleosis (IM) - pharyngitis, lymphadenopathy, and prolonged fatigue. The virus then establishes latency in B-lymphocytes, persisting for life in virtually all infected individuals.

The downstream oncological risk is substantial. EBV is causally associated with Burkitt lymphoma, Hodgkin lymphoma, post-transplant lymphoproliferative disease (PTLD), gastric carcinoma, and nasopharyngeal carcinoma. Collectively, EBV-attributable cancers account for 1-2% of the global cancer burden and approximately 140,000-200,000 deaths annually. More recently, EBV has been implicated as a necessary antecedent in the development of multiple sclerosis - a finding that, if confirmed, would materially expand the addressable indication for a prophylactic vaccine.

EBV-attributable cancer deaths · annual
140-200k

Estimated annual global deaths from EBV-attributable cancers. EBV is also implicated as a potential causative factor in multiple sclerosis development.

Proof of Concept - and a Gap

GSK demonstrated proof of concept for EBV vaccination in a Phase 2 study using a recombinant gp350 subunit vaccine (Sokal EM et al, Journal of Infectious Diseases, 2007). The vaccine reduced symptomatic IM by approximately 78% but did not prevent EBV infection itself. GSK subsequently ceased active development, leaving a decade-long gap in industrial EBV vaccine activity. The data remain important as they establish that reducing IM disease burden is achievable and provide a benchmark for mRNA-based candidates.

Moderna's mRNA Programmes

Moderna announced plans to advance mRNA-1189, a prophylactic vaccine targeting multiple EBV glycoproteins, and mRNA-1195, a therapeutic vaccine for latently infected individuals. This dual-programme approach reflects the different commercial rationales - prophylaxis primarily benefits seronegative adolescents and young adults (and potentially MS prevention), while a therapeutic vaccine targets the larger pool of already-infected adults at risk of EBV-associated malignancies.

VacZine Analytics' market model in VAMV056 quantifies the addressable population for both indications across Western economies, with forecasts to 2040 and distinct target product profile scenarios for prophylactic and therapeutic use.

"Moderna's dual EBV programme - prophylactic and therapeutic - is the most consequential entry into this space since GSK's proof-of-concept work a decade ago."